Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Impax Laboratories (IPXL) PT Raised to $20 at Cowen Following Strong 2Q
August 9, 2017 1:54 PM EDTCowen raised its price target on Impax Laboratories (NASDAQ: IPXL) to $20.00 (from $12.00) while maintaining a Market Perform rating.
Impax reported 2Q results that were above expectations as total revenues of $202MM were $6MM above the Street's estimate. The better revenues and better... More
Impax Laboratories (IPXL) Tops Q2 EPS by 4c
August 9, 2017 7:08 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.18, $0.04 better than the analyst estimate of $0.14. Revenue for the quarter came in at $202.1 million versus the consensus estimate of $195.62 million.
GUIDANCE:
Impax Laboratories sees FY2017 EPS of $0.55-$0.70, versus the consensus of... More
